Results of Lumega-Z Data to be Presented at ARVO
April 17 2019 - 9:01AM
Guardion Health Sciences, Inc.’s (the “Company”) Scientific
Advisory Board member, Dr. William Sponsel will be presenting an
abstract at the Association for Research in Vision and
Ophthalmology (“ARVO”) 2019 Annual Meeting in Vancouver, Canada,
which will be held from April 28, 2019 to May 2, 2019. The abstract
(the “Abstract”) is titled “Effect of oral Lumega-Z on pericentral
FDT function in IOP-stabilized severe glaucoma” and has been made
available on ARVO’s website at
https://www.arvo.org/annual-meeting/program/online-planner/
The study assessed the potential utility of the
Company’s medical food product, Lumega-Z, which is designed to
restore the macular protective pigment layer. The abstract
concludes that in patients who had ordered 12 consecutive month’s
supply of Lumega-Z, Lumega-Z treatment was associated with
significant improvement in visual field function among patients
with severe glaucoma who had previously shown degeneration despite
having had excellent intraocular pressure control.
The study was conducted at (i) the School of
Medicine, Universidad Autonoma de Guadalajara in Guadalajara,
Mexico, (ii) the Visual Sciences/Biomedical Engineering, UIW/UTSA
in San Antonio, Texas, and (iii) the Ophthalmology Department of
the New York Medical College.
About Guardion Health Sciences,
Inc.
Guardion is an ocular health sciences company
that develops, formulates and distributes condition-specific
medical foods supported by evidence-based protocols, with an
initial medical food product that addresses a depleted macular
protective pigment, a known risk factor for age-related macular
degeneration (“AMD”), and a significant component of functional
vision performance. Guardion Health Sciences, Inc. has also
developed a proprietary medical device, the MapcatSF®, which
accurately measures the macular pigment density, therefore
providing the only two-pronged evidence-based protocol for the
treatment of a depleted macular protective pigment.
About
VectorVision®
VectorVision® specializes in the standardization
of contrast sensitivity, glare sensitivity, low contrast acuity,
and ETDRS acuity vision testing. Its patented standardization
system provides the practitioner or researcher the ability to
delineate very small changes in visual capability, either as
compared to the population or from visit to visit. VectorVision®’s
CSV-1000 device is considered the standard of care for clinical
trials. VectorVision® is a wholly-owned subsidiary of Guardion.
Forward-Looking Statement
Disclaimer
With the exception of the historical information
contained in this news release, the matters described herein may
contain forward-looking statements within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended. These statements
involve unknown risks and uncertainties that may individually or
materially impact the matters discussed herein for a variety of
reasons that are outside the control of the Company, including, but
not limited to, the Company’s ability to raise sufficient financing
to implement its business plan and its ability to successfully
develop and commercialize its proprietary products and
technologies. Readers are cautioned not to place undue reliance on
these forward-looking statements, as actual results could differ
materially from those described in the forward-looking statements
contained herein. Readers are urged to read the risk factors set
forth in the Company’s filings with the SEC, which are available at
the SEC’s website (www.sec.gov). The Company disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Company Contact:
Michael Favish
Chief Executive Officer
Telephone: (858) 605-9055 x 201
E-mail: mfavish@guardionhealth.com
Investor Relations Contact:
Matthew Abenante
Porter, LeVay & Rose
Telephone: (212) 564-4700
E-mail: matthew@plrinvest.com
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Sep 2023 to Sep 2024